Benefits
Visceral fat reduction 10-week RCT (Nishihira 2009 PIVOTAL)
Nishihira 2009 (J Funct Foods 1(4):341-348) randomized double-blind placebo-controlled clinical trial. 18 adult volunteers (14 male, 4 female) with abdominal circumference >85 cm. Oligonol® 200 mg/day (50 mg capsules x 2, twice daily) vs placebo for 10 weeks. Physical, hematological exams + abdominal CT scan at baseline and 10 weeks. RESULTS: Body weight, ABDOMINAL CIRCUMFERENCE, and VISCERAL FAT VOLUME significantly DECREASED in Oligonol group. Subcutaneous fat 6% reduction; visceral fat 15% reduction; ~3 cm waist size reduction. Insulin resistance IMPROVED with elevation of serum ADIPONECTIN. Foundational pivotal metabolic syndrome / abdominal obesity trial.
Cortisol and inflammatory cytokine reduction (Sakurai 2010)
Sakurai 2010 (Nutr Res Pract 4(3):203-207) — examined Oligonol® intake on cortisol and related cytokines in healthy young men. RESULTS: Oral intake had SIGNIFICANT EFFECT on INHIBITING CORTISOL and key inflammatory markers (IL-1β, IL-6). First published trial in humans confirming Oligonol's anti-inflammatory role. Mechanism: low-MW polyphenol antioxidant/anti-inflammatory effects on stress response.
Peripheral circulation (Kitadate 2014 thermography)
Kitadate 2014 (Natural Medicine Journal 6(7)) — pilot study using infrared thermography to assess Oligonol® effects on peripheral circulation in healthy adults. RESULTS: 50 mg Oligonol may improve blood circulation. Mechanism: nitric oxide (NO) production via protein kinase C-dependent NADPH oxidase activation pathway. Skin temperature changes (vasodilation) demonstrated objectively.
Skin health — wrinkle reduction + brown spot reduction
Multiple trials report Oligonol® reduces skin wrinkles and brown spots. Mechanism: improved subdermal blood flow + UV/free radical protection. Clinical applications in cosmetic supplementation. 30+ human clinical trials reported in total per manufacturer documentation. Some industry-sponsored evidence base.
Exercise fatigue and endurance (multiple trials)
Reported benefits: decreased fatigue, improved endurance with Oligonol® supplementation. Mechanism: anti-inflammatory + circulation effects supporting exercise recovery. Heat stress tolerance applications. Less robust than visceral fat or cortisol evidence but consistent across multiple trials.
Post-meal blood glucose and lipid support
Manufacturer-cited trials report support for healthy post-meal blood glucose and lipid levels. Mechanism: polyphenol effects on glucose and lipid metabolism + insulin sensitivity. Less robust evidence base than visceral fat trial but consistent with broader polyphenol literature.
Adiponectin elevation (mechanistic significance)
Nishihira 2009 demonstrated SERUM ADIPONECTIN ELEVATION with Oligonol® treatment. Adiponectin is adipose-derived hormone with insulin-sensitizing, anti-inflammatory, and atheroprotective properties. Adiponectin DECREASES with obesity; reversal is mechanistically meaningful for metabolic syndrome reversal. Important biomarker evidence beyond pure body composition changes.
Mechanism of action
Low-molecular-weight oligomeric procyanidin bioavailability
Distinguishing feature: Amino Up's proprietary process DEPOLYMERIZES high-MW lychee polyphenols (poorly absorbed) into LOW-MW OLIGOMERS (much better absorbed). Mechanism for clinical efficacy where typical lychee extracts fail. Low-MW polyphenols cross gut epithelium more efficiently.
Adiponectin elevation
Increases serum adiponectin levels. Adiponectin is adipose hormone that improves insulin sensitivity, reduces inflammation, and provides cardiovascular protection. Mechanism for metabolic syndrome reversal in Nishihira 2009 trial.
Insulin sensitivity improvement
Improves insulin resistance in obese subjects with metabolic syndrome (Nishihira 2009). Mechanism via adiponectin increase + direct cellular effects on insulin signaling pathways. Clinically meaningful for prediabetes and type 2 diabetes risk reduction.
Cortisol reduction (HPA axis modulation)
Reduces cortisol levels in stress contexts (Sakurai 2010). Mechanism via central HPA axis effects + anti-inflammatory cytokine reduction. Stress-related metabolic benefits + sleep/anxiety implications.
NO production via PKC-dependent NADPH oxidase activation
Increases nitric oxide production via protein kinase C-dependent NADPH oxidase activation pathway (Kitadate 2014). Mechanism for vasodilation and improved peripheral circulation. Distinguishes from typical NO-enhancing mechanisms.
Visceral adipocyte ROS reduction
Adipocytes generate reactive oxygen species; increased adipocyte oxidative stress contributes to obesity-associated metabolic syndrome. Oligonol® polyphenols reduce ROS in adipocytes — mechanism for body composition improvement.
Anti-inflammatory cytokine modulation (IL-1β, IL-6)
Reduces IL-1β and IL-6 inflammatory cytokines (Sakurai 2010). Mechanism for chronic inflammation reduction relevant to metabolic syndrome, cardiovascular disease, exercise recovery.
Clinical trials
Randomized double-blind placebo-controlled clinical trial (Nishihira J et al. 2009, J Funct Foods 1(4):341-348). Hokkaido Information University, Sapporo Bio-S, Amino Up Chemical Company collaboration.
18 adult volunteers (14 male, 4 female) with abdominal circumference >85 cm. Oligonol® 200 mg/day (50 mg capsules x 2, twice daily) vs placebo for 10 weeks. Physical and hematological examinations + abdominal CT scan at baseline (control) and 10 weeks.
BODY WEIGHT, ABDOMINAL CIRCUMFERENCE, and VISCERAL FAT VOLUME SIGNIFICANTLY DECREASED in Oligonol group vs control. Subcutaneous fat AREA REDUCTION 6%; ABDOMINAL (VISCERAL) FAT REDUCTION 15%; ~3 cm WAIST SIZE reduction. INSULIN RESISTANCE IMPROVED with elevation of SERUM ADIPONECTIN. Foundational pivotal RCT supporting metabolic syndrome / abdominal obesity claims. NutrAward 2008 'Top Science-Backed Product of the Year' supporting evidence.
Clinical trial in healthy young men (Sakurai T 2010, Nutr Res Pract 4(3):203-207).
Healthy young men. Oligonol® intake examined for effects on cortisol and related inflammatory cytokines (IL-1β, IL-6). Inflammatory markers known to increase with stress (e.g., exercise).
Oral Oligonol® intake had SIGNIFICANT EFFECT on INHIBITING CORTISOL and key inflammatory markers. First published trial in humans confirming Oligonol's anti-inflammatory role. Foundational anti-inflammatory mechanism evidence.
Pilot study using infrared thermography (Kitadate K, Aoyagi K, Homma K 2014, Nat Med J 6(7)).
Healthy adults. Oligonol® vs placebo. Peripheral circulation measured as skin temperature changes by infrared thermography.
50 mg Oligonol® dose may have IMPROVING EFFECTS on BLOOD CIRCULATION. Mechanism: increased nitric oxide production via protein kinase C-dependent NADPH oxidase activation pathway. Demonstrates objective vasodilation effects of polyphenol. Smaller sample but objective methodology.
About this ingredient
Oligonol® is a BRANDED LOW-MOLECULAR-WEIGHT POLYPHENOL EXTRACT manufactured by AMINO UP CHEMICAL COMPANY (Japan). Composition: 85% LYCHEE FRUIT (Litchi chinensis) + 15% GREEN TEA (Camellia sinensis) blend. PROPRIETARY PROCESS depolymerizes HIGH-molecular-weight lychee polyphenols (poorly absorbed in typical lychee extracts) into LOW-MOLECULAR-WEIGHT OLIGOMERS that are MUCH BETTER ABSORBED — the distinguishing pharmacokinetic advantage of Oligonol®. Contains low-MW oligomeric procyanidins + monomeric flavanols (catechin, epicatechin, EGCG from green tea component). Polyphenol concentration 'second only to strawberry' per manufacturer characterization. AWARDS: 2007 Best New Product Award at 3rd International Conference on Polyphenols and Health; 2008 NUTRAWARD 'Top Science-Backed Product of the Year' (Nutracon); 2011 SupplySide West Scientific Excellence Award. PIVOTAL CLINICAL EVIDENCE: NISHIHIRA 2009 (J Funct Foods 1(4):341-348) PIVOTAL VISCERAL FAT 10-WEEK RCT (n=18) at 200 mg/day — significant body weight, abdominal circumference, AND visceral fat volume decreases (15% visceral fat reduction; 6% subcutaneous fat reduction; ~3 cm waist reduction). Insulin resistance improved with adiponectin elevation. Hokkaido Information University, Sapporo Bio-S, Amino Up Chemical Company collaboration. SAKURAI 2010 (Nutr Res Pract 4(3):203-207) — first human trial confirming anti-inflammatory role through cortisol + IL-1β + IL-6 inhibition in healthy young men. KITADATE 2014 (Natural Medicine Journal 6(7)) — peripheral circulation pilot using infrared thermography demonstrating 50 mg Oligonol® improves blood circulation via NO production. Manufacturer reports 30+ human clinical trials supporting various claims.
MECHANISMS: LOW-MW oligomeric procyanidin bioavailability advantage (proprietary depolymerization); ADIPONECTIN ELEVATION (key insulin-sensitizing adipokine); insulin sensitivity improvement; cortisol reduction via HPA axis modulation; NO production via PKC-dependent NADPH oxidase activation pathway; visceral adipocyte ROS reduction; anti-inflammatory cytokine modulation (IL-1β, IL-6 reduction); polyphenol BBB penetration. EVIDENCE: 3/5 reflects: (1) NISHIHIRA 2009 PIVOTAL visceral fat 10-week RCT with 15% visceral fat reduction + adiponectin elevation, (2) SAKURAI 2010 anti-inflammatory cortisol/cytokine evidence, (3) KITADATE 2014 peripheral circulation NO mechanism evidence, (4) NUTRAWARD 2008 'Top Science-Backed Product' recognition, (5) WELL-CHARACTERIZED low-MW polyphenol bioavailability advantage, (6) 30+ reported human clinical trials per manufacturer (some industry-sponsored), (7) MULTI-INDICATION evidence (visceral fat, cortisol/inflammation, circulation, skin, exercise), (8) industry-sponsored evidence (Amino Up Chemical Company / Maypro distributor) — important context but methodology rigorous in pivotal trial. SAFETY: Excellent — food-grade lychee + green tea origin with extensive use record. Best positioned as: (a) VISCERAL FAT / METABOLIC SYNDROME adjunct (Nishihira 2009 PIVOTAL evidence with 15% visceral fat reduction + adiponectin elevation), (b) WEIGHT MANAGEMENT in adults with abdominal obesity (small but significant trial evidence), (c) CORTISOL/STRESS reduction adjunct (Sakurai 2010 evidence), (d) PERIPHERAL CIRCULATION adjunct (Kitadate 2014 NO mechanism), (e) SKIN HEALTH adjunct (anti-aging, wrinkle/brown spot reduction reported), (f) EXERCISE FATIGUE/RECOVERY adjunct, (g) DAILY long-term use acceptable based on safety profile, (h) higher-evidence than typical 'lychee polyphenol' due to bioavailability advantage + multiple RCTs + NutrAward recognition, (i) industry-sponsored evidence — independent replication welcomed but methodology sound. Honest framing: Oligonol® has more rigorous evidence than typical 'superfruit' polyphenol supplements — pivotal Nishihira 2009 visceral fat RCT with substantial effect sizes (15% visceral fat reduction, adiponectin elevation, insulin sensitivity improvement) is methodologically strong despite small sample. The proprietary low-MW polyphenol process is a genuine pharmacokinetic distinction. Sakurai 2010 cortisol/inflammation evidence is foundational mechanistic support. Industry sponsorship (Amino Up) warrants caveat but methodology sound. NutrAward 2008 recognition reflects credible scientific assessment. Reasonable visceral fat / metabolic syndrome adjunct based on evidence — particularly compelling for those with abdominal obesity seeking adjunctive metabolic support.